Dee Barber McManus has joined OBX Bank, a division of Monarch Bank, as assistant vice president and retail office manager of OBX Bank's second banking office in Nags Head. McManus has been in the banking industry for 17 years.
Is COVID Optimism Finally Overtaking Pessimism? Harvard Experts Weigh In plos.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from plos.org Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
NEW YORK, Feb. 22, 2021 /PRNewswire/ BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it recently met with senior leadership from the U.S. Food and Drug Administration (FDA) and received FDA feedback on a high-level data summary from the NurOwn (autologous MSC-NTF cells) ALS Phase 3 clinical trial. The FDA concluded from their initial review that the current level of clinical data does not provide the threshold of substantial evidence that FDA is seeking to support a Biologics License Application (BLA). In addition, the FDA advised that this recommendation does not preclude Brainstorm from proceeding with a BLA submission.
NEW YORK, Feb. 22, 2021 /PRNewswire/ BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it recently met with. | February 27, 2021
Aevitas Therapeutics Appoints Markus Peters, Ph.D., M.Sc., as Chief Executive Officer
February 22, 2021 08:00 ET | Source: Aevitas Therapeutics, Inc. Aevitas Therapeutics, Inc.
Catherine Bowes Rickman, Ph.D., FARVO, a leading age-related macular degeneration researcher, appointed to Scientific Advisory Board
NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) Aevitas Therapeutics, Inc. (“Aevitas”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) partner company focused on the development of novel gene therapy approaches for complement-mediated diseases, today announced the appointment of Markus Peters, Ph.D., M.Sc., as President and Chief Executive Officer. Dr. Peters was most recently the Chief Operating Officer of Gemini Therapeutics after serving as the Chief Commercial Officer of Agilis Biotherapeutics. Dr. Peters will lead the Company as it advances its proprietary platform designed to deliver engineered, fully functional, shortened comple